ES2572388T3 - Heterodímeros del MHC de clase II solubles funcionales estabilizados por enlaces disulfuro - Google Patents
Heterodímeros del MHC de clase II solubles funcionales estabilizados por enlaces disulfuroInfo
- Publication number
- ES2572388T3 ES2572388T3 ES11730044T ES11730044T ES2572388T3 ES 2572388 T3 ES2572388 T3 ES 2572388T3 ES 11730044 T ES11730044 T ES 11730044T ES 11730044 T ES11730044 T ES 11730044T ES 2572388 T3 ES2572388 T3 ES 2572388T3
- Authority
- ES
- Spain
- Prior art keywords
- mhc
- heterodimers
- stabilized
- chain
- disulfide bonds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000043131 MHC class II family Human genes 0.000 abstract 2
- 108091054438 MHC class II family Proteins 0.000 abstract 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Una molécula de MHC de clase II recombinante, que comprende: (i) toda o parte de la parte extracelular de una cadena α de MHC de clase II; (ii) toda o parte de la parte extracelular de una cadena β de MHC de clase II; en la que (i) y (ii) proporcionan un dominio de unión a péptido funcional y en la que (i) y (ii) se unen mediante un enlace disulfuro entre restos de cisteína localizados en el dominio α2 de dicha cadena α y el dominio β2 de dicha cadena β, en la que dichos restos de cisteína no están presentes en dominios α2 y β2 de MHC de clase II nativo, y en la que dicha molécula recombinante no comprende un motivo de cremallera de leucina.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30572810P | 2010-02-18 | 2010-02-18 | |
| GBGB1002730.8A GB201002730D0 (en) | 2010-02-18 | 2010-02-18 | Product |
| US31657610P | 2010-03-23 | 2010-03-23 | |
| PCT/GB2011/050325 WO2011101681A2 (en) | 2010-02-18 | 2011-02-18 | Disulphide bond-stabilized functional soluble mhc class ii heterodimers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2572388T3 true ES2572388T3 (es) | 2016-05-31 |
Family
ID=42113985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11730044T Active ES2572388T3 (es) | 2010-02-18 | 2011-02-18 | Heterodímeros del MHC de clase II solubles funcionales estabilizados por enlaces disulfuro |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8828379B2 (es) |
| EP (1) | EP2536746B1 (es) |
| JP (1) | JP5537675B2 (es) |
| KR (1) | KR101647176B1 (es) |
| CN (1) | CN102947330B (es) |
| AU (1) | AU2011217027B2 (es) |
| CA (1) | CA2789492C (es) |
| CY (1) | CY1117697T1 (es) |
| DK (1) | DK2536746T3 (es) |
| ES (1) | ES2572388T3 (es) |
| GB (1) | GB201002730D0 (es) |
| HR (1) | HRP20160475T1 (es) |
| HU (1) | HUE027952T2 (es) |
| PL (1) | PL2536746T3 (es) |
| RS (1) | RS54744B1 (es) |
| RU (1) | RU2604813C2 (es) |
| SI (1) | SI2536746T1 (es) |
| WO (1) | WO2011101681A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| PT3167065T (pt) * | 2014-07-09 | 2020-07-01 | Lupin Ltd | Sistema de expressão bacteriana dual cistrónica |
| US11059880B2 (en) | 2015-06-30 | 2021-07-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with MHC chimeric receptors and methods of use in immunotherapy |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
| BR112019009477A2 (pt) * | 2016-11-09 | 2019-07-30 | Uti Lp | moléculas de classe ii de pmhc recombinantes |
| CA3060526A1 (en) | 2017-04-27 | 2018-11-01 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| DE102018122546B3 (de) | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| CN113366311A (zh) * | 2018-09-28 | 2021-09-07 | 丹麦技术大学 | 使用可加载的检测分子的高通量表位鉴定和t细胞受体特异性测定 |
| TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3719033A1 (en) * | 2019-04-02 | 2020-10-07 | imusyn GmbH & Co. KG | Stabilized mhc i |
| CA3151949A1 (en) * | 2019-08-21 | 2021-02-25 | Uti Limited Partnership | Improved recombinant pmhc molecules |
| US20210155670A1 (en) * | 2019-09-13 | 2021-05-27 | The Regents Of The University Of California | Systems and methods for the preparation of peptide-mhc-i complexes with native glycan modifications |
| JP2023504172A (ja) * | 2019-12-02 | 2023-02-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用 |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| DE102020109447A1 (de) | 2020-04-03 | 2021-10-07 | Jacobs University Bremen Ggmbh | Synthetisches mhc-klasse-ii-protein |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990010457A1 (en) | 1989-03-14 | 1990-09-20 | New York University | Method of treating hiv infections using immunotoxins |
| DE69730038T2 (de) * | 1996-08-16 | 2004-11-25 | The President And Fellows Of Harvard College, Cambridge | Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen |
| AU741130B2 (en) * | 1997-09-16 | 2001-11-22 | Oregon Health Sciences University | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| TR200003391T2 (tr) * | 1998-05-19 | 2001-02-21 | Avidex Limited | Çözünür T hücresi reseptörü |
| RU2303264C2 (ru) * | 2001-02-19 | 2007-07-20 | Мерк Патент Гмбх | Способ идентификации эпитопов т-клеток и его применение для получения молекул со сниженной иммуногенностью |
| GB2392158B (en) * | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| CA2537759C (en) * | 2003-09-05 | 2015-03-24 | Oregon Health & Science University | Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| WO2006102170A2 (en) * | 2005-03-18 | 2006-09-28 | Oregon Health & Science University | Recombinant mhc molecules useful for manipulation of antigen-specific t cells |
| US9249202B2 (en) * | 2006-08-11 | 2016-02-02 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in immune disorders |
| EP2097789B1 (en) * | 2006-12-01 | 2012-08-01 | Carl Zeiss SMT GmbH | Optical system with an exchangeable, manipulable correction arrangement for reducing image aberrations |
| AU2008290537B2 (en) | 2007-08-20 | 2014-04-03 | Nextera As | pVII phage display |
-
2010
- 2010-02-18 GB GBGB1002730.8A patent/GB201002730D0/en not_active Ceased
-
2011
- 2011-02-18 HU HUE11730044A patent/HUE027952T2/en unknown
- 2011-02-18 RS RS20160323A patent/RS54744B1/sr unknown
- 2011-02-18 PL PL11730044T patent/PL2536746T3/pl unknown
- 2011-02-18 CN CN201180011237.4A patent/CN102947330B/zh active Active
- 2011-02-18 KR KR1020127024287A patent/KR101647176B1/ko active IP Right Grant
- 2011-02-18 AU AU2011217027A patent/AU2011217027B2/en active Active
- 2011-02-18 ES ES11730044T patent/ES2572388T3/es active Active
- 2011-02-18 WO PCT/GB2011/050325 patent/WO2011101681A2/en active Application Filing
- 2011-02-18 CA CA2789492A patent/CA2789492C/en active Active
- 2011-02-18 US US13/579,887 patent/US8828379B2/en active Active
- 2011-02-18 DK DK11730044.2T patent/DK2536746T3/en active
- 2011-02-18 SI SI201130815A patent/SI2536746T1/sl unknown
- 2011-02-18 EP EP11730044.2A patent/EP2536746B1/en active Active
- 2011-02-18 JP JP2012553409A patent/JP5537675B2/ja active Active
- 2011-02-18 RU RU2012138302/10A patent/RU2604813C2/ru active
-
2014
- 2014-07-14 US US14/331,014 patent/US9056920B2/en active Active
-
2016
- 2016-05-04 HR HRP20160475TT patent/HRP20160475T1/hr unknown
- 2016-05-11 CY CY20161100397T patent/CY1117697T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2536746B1 (en) | 2016-04-20 |
| CY1117697T1 (el) | 2017-05-17 |
| KR101647176B1 (ko) | 2016-08-09 |
| AU2011217027B2 (en) | 2015-02-05 |
| CA2789492A1 (en) | 2011-08-25 |
| HRP20160475T1 (hr) | 2016-06-03 |
| WO2011101681A3 (en) | 2011-12-08 |
| DK2536746T3 (en) | 2016-05-30 |
| RU2604813C2 (ru) | 2016-12-10 |
| WO2011101681A2 (en) | 2011-08-25 |
| PL2536746T3 (pl) | 2016-08-31 |
| EP2536746A2 (en) | 2012-12-26 |
| RS54744B1 (sr) | 2016-10-31 |
| JP5537675B2 (ja) | 2014-07-02 |
| RU2012138302A (ru) | 2014-03-27 |
| SI2536746T1 (sl) | 2016-09-30 |
| AU2011217027A1 (en) | 2012-09-06 |
| KR20130009782A (ko) | 2013-01-23 |
| GB201002730D0 (en) | 2010-04-07 |
| US20130171668A1 (en) | 2013-07-04 |
| US20140349315A1 (en) | 2014-11-27 |
| CN102947330B (zh) | 2015-09-16 |
| US8828379B2 (en) | 2014-09-09 |
| US9056920B2 (en) | 2015-06-16 |
| CN102947330A (zh) | 2013-02-27 |
| JP2013519721A (ja) | 2013-05-30 |
| HUE027952T2 (en) | 2016-11-28 |
| CA2789492C (en) | 2017-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2572388T3 (es) | Heterodímeros del MHC de clase II solubles funcionales estabilizados por enlaces disulfuro | |
| ES2528346T3 (es) | Derivado de péptido insulinotrópico en el que se ha modificado su aminoácido N-terminal | |
| CL2018003148A1 (es) | Proteínas de fusión y usos de las mismas. | |
| PE20190743A1 (es) | Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib | |
| NI201300143A (es) | Coagonista del receptor de glucagón/glp-1 | |
| CR20120366A (es) | Proteínas de enlace a antigenos humanas que enlazan beta-klotho, receptores fgf y complejos de los mismos | |
| CL2014000400A1 (es) | Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11). | |
| CY1115413T1 (el) | Ανασυνδυασμενη fsh η οποια περιλαμβανει αλφα 2,3- και αλφα 2',6-sialylation | |
| PE20171325A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
| ME01136B (me) | Antitumorske kombinacije koje sadrže antitijela koja specifično prepoznaju cd38 i melfalan | |
| PE20120532A1 (es) | ANTICUERPOS ANTI-ActRIIB | |
| MX2016007063A (es) | Peptidos terapeuticos. | |
| EA201591454A1 (ru) | Связывающие внеклеточный матрикс синтетические пептидогликаны | |
| PE20230404A1 (es) | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo | |
| PA8811501A1 (es) | Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado | |
| JP2007045829A5 (es) | ||
| CO6351811A2 (es) | La proteina de tuberculosis rv2386c, composiciones y usos de la misma | |
| PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
| UA118558C2 (uk) | Пептидна сполука | |
| ES2585328T3 (es) | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis | |
| EA201792245A1 (ru) | Биоконъюгаты и их применения | |
| EA201170242A1 (ru) | Модифицированные бычьи полипептиды g-csf и их применение | |
| BRPI0818288A2 (pt) | Proteínas conjugadas e peptídeos. | |
| CY1115140T1 (el) | Πεπτιδια και η χρηση τους | |
| UY35444A (es) | Anticuerpos anti-tnf alfa mutados y métodos para su utilización |